BioNTech publishes proof-of-concept data for BNT211 CAR-T cell therapy
Category: #health  By Mateen Dalal  Date: 2020-01-04
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

BioNTech publishes proof-of-concept data for BNT211 CAR-T cell therapy

The report will contain data of CAR-T product candidate called BNT211, an autologous CAR-T cell therapy

BioNTech SE, a biotechnology firm based in Germany, recently announced a publication in Science regarding a therapeutic CAR-T approach for solid tumors that uses CAR-T cell amplifying RNA Vaccine, also called CARVac introduced by the company. The report offers preclinical proof-of-concept data for the company’s first CAR-T product candidate called BNT211 which is an autologous CAR-T cell therapy.

It essentially targets oncofetal antigen Claudin 6 (CLDN6) as well as outlines CARVac as an RNA vaccine approach that is widely applicable for the improvement of the efficacy of the CAR-T cell therapies.

Reportedly, CAR-T cell has exhibited considerable clinical efficacy in blood cancers but still tends to face challenges in regards with solid tumors that includes a limited number of identified cancer-specific solid tumors, insufficient persistence of CAR-T cells and inefficient CAR-T cell infiltration into solid tumors.

BioNTech has been aiming to overpower such hurdles by targeting the tumor-specific antigen expressed in several solid tumors, CLDN6, which when combined with an RNA vaccine will promote persistence, efficacy, and amplification of CAR-T cells in vivo.

CAR-T cell therapy combined with CARVac will be underlining the value of cross-platform synergies that would address major challenges for the development of cancer treatment.

Sources confirm that BioNTech has planned to commence Phase 1/2 clinical trial, its first-in-human trial for BNT211, later in the year in solid tumors such as testicular, lung cancer, ovarian and uterine. The manufacturing shall be conducted in-house at the state-of-the-art cell therapy facility BioNTech, which is GMP certified, to support the clinical trials of BNT211. The GMP plant is a certified cell therapy and manufacturing facility located in Idar-Oberstein, Germany, that has been operating since 1999.

BioNTech had initiated a capacity expansion at the facility in the year 2018 and it expects it to be completed by 2020.

 

Source Credit- https://investors.biontech.de/news-releases/news-release-details/biontech-announces-publication-preclinical-data-first-kind-car-t

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Chevrolet Camaro could be replaced by a potential all-electric sedan

Chevrolet Camaro could be replaced by a potential all-electric sedan

By Mateen Dalal

Reportedly, General Motors Company is planning to replace the Chevrolet Camaro with an all-electric performance sedan in a few years with the existing model likely to be phased out by 2024. There have many reports about discontinuing the Camaro&rsqu...

Sequoia India launches Spark Fellowship to support female entrepreneurs

Sequoia India launches Spark Fellowship to support female entrepreneurs

By Mateen Dalal

The Spark fellowship program is for women entrepreneurs in India and Southeast Asia. The year-long program is aimed at bringing more gender diversity and supporting startups led by women. Sequoia Capital has recently revealed the launch of a yea...

Biden names avid tech critic Jonathan Kanter as DOJ antitrust chief

Biden names avid tech critic Jonathan Kanter as DOJ antitrust chief

By Mateen Dalal

U.S. President Joe Biden will reportedly nominate Jonathan Kanter, a competition lawyer, and fervid Google critic, to head the antitrust division of the Justice Department. Kanter has been actively representing several companies in competition cases...